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Host responses against metazoan parasites or an array of environmental substances elicit type 2 immunity. Despite its protective function, type 2 immunity also drives allergic diseases. The mechanisms that regulate the magnitude of the type 2 response remain largely unknown. Here, we show that genetic ablation of a receptor tyrosine kinase encoded by Tyro3 in mice or the functional neutralization of its ortholog in human dendritic cells resulted in enhanced type 2 immunity. Furthermore, the TYRO3 agonist PROS1 was induced in T cells by the quintessential type 2 cytokine, interleukin-4. T cell-specific Pros1 knockouts phenocopied the loss of Tyro3. Thus, a PROS1-mediated feedback from adaptive immunity engages a rheostat, TYRO3, on innate immune cells to limit the intensity of type 2 responses.
T he type 2 immune response is the major protective mechanism against metazoan parasites and is simultaneously characteristic of allergy and allergic diseases (1) (2) (3) . The mechanism that regulates the intensity of this response is not well understood. Because genetic predisposition is an important risk factor for allergic diseases, we performed a metaanalysis of three independent genome-wide association studies (GWASs) of Latinos and African Americans with asthma. Multiple intronic variants in TYRO3 were associated with asthma ( fig. S1A and table S1). The most significant association was at a single-nucleotide polymorphism (SNP) located within several putative transcription factor-binding sites in TYRO3 (fig. S1, A and B). TYRO3 is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinase (RTK) subgroup. AXL and MERTK have recently been identified as pleiotropic negative regulators of the immune response (4-7), but our meta-analysis did not reveal an association with asthma ( fig. S1 , C and D). The molecular functions of TYRO3 in immune regulation remain largely uncharacterized. Because TYRO3 shows substantial sequence identity with AXL and MERTK, we hypothesized that TYRO3 may limit the magnitude of the immune response in the context of type 2 immunity.
To test this hypothesis, we first used a house dust mite (HDM) model of allergic airway inflammation. HDM-sensitized wild-type (WT) mice developed classical signs of allergic asthma, including influx of eosinophils and lymphocytes in the bronchoalveolar lavage (BAL) fluid and lung ( Fig. 1A and fig. S2 , A to C), as well as expansion of CD4 + T cells and effector memory cells in the mediastinal lymph nodes (medLNs) ( fig. S2D ). We also challenged mice lacking either TYRO3 alone or both AXL and MERTK with HDM. Remarkably, HDM-sensitized Tyro3 -/-mice displayed a more robust type 2 response, as reflected by a further increase in leukocytes and eosinophils in BAL fluid and lung (Fig. 1A  and fig. S2C ). This was accompanied by increased total and effector memory CD4 + T cells in the medLNs (fig. S2D ); higher percentages of CD4 + T cells producing type 2 cytokines-such as interleukin 4 (IL-4), IL-5, and IL-13-but not the type I cytokine interferon-g (IFN-g) (Fig. 1B) and higher serum immunoglobulin E (IgE) (Fig.  1C) . These exacerbated cellular and humoral type 2 responses correlated with increased lung histopathological score (Fig. 1D) . A role of AXL has been described in respiratory infections (8, 9) . However, the ablation of this receptor in conjunction with MERTK (Axl
) did not result in increased susceptibility of mice to HDM (Fig. 1A and fig. S2 ).
To (Fig. 2C) , larger amounts of type 2 cytokines from mesenteric LNs (mLNs) ( fig. S3D) , and enhanced L3-and L5-specific IgG1 antibodies and total IgE humoral response (Fig. 2D) . By days 2, 3, and 7, Tyro3 -/-mice had fewer worms in the lungs and small intestines, which indicates accelerated clearance of the parasite (Fig. 2E) 
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Lymphocytes (x10 In all panels, each data point is from a different mouse or human. Means ± SEM. Data were analyzed using unpaired Student's t test [(B), (C), and (E)] or paired Student's t test (D).*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., nonsignificant. (E) Kinetics of the total parasite numbers in the lung and small intestine (S.I.) at 1 dpi, 2 dpi, 3 dpi, and 7 dpi. Data are representative of two or three independent experiments. In all graphs, each data point is from a different animal, means ± SEM. Data were analyzed using unpaired Student's t test [(A) to (E)]. *P < 0.05; **P < 0.01; n.s., nonsignificant.
which indicated that WT and Tyro3 -/-DCs migrated and survived to equal degree ( fig. S7B) (Fig. 3, B and C) . When OVA-loaded WT or Tyro3 -/-DCs were transferred during priming, only Tyro3 -/-PDL2 + DCs led to an enhanced response in recipient mice ( fig. S8) .
Comparison of the most differentially transcribed genes between DCs that can induce type 2 immunity and those that cannot revealed that a subset of chemokines-CCL22, CCL17, and CCL5-are highly expressed in PDL2 + DCs (14) . Some of these chemokines actively promote type 2 immunity, as neutralization of their function results in a reduction of the response (18, 19) . We detected a significant increase in the production of these chemokines when either Tyro3 -/-
PDL2
+ or PDL2 -DCs were cocultured with activated CD4 + T cells in comparison with respective WT DCs (Fig. 3D) . Consistent with the requirement for OX40L in inducing T H 2 responses (15), Tyro3 -/-PDL2 + DCs had higher expression of OX40L after transfer relative to WT PDL2 + DCs, whereas CD86 and CD40 levels were comparable ( fig. S7, C and D) . Finally, circulating human CD11c hi CD11b lo DCs also expressed TYRO3. This expression was significantly increased in DCs from helminth-infected patients in comparison with healthy controls (Fig. 3E) . In summary, our results indicate that the absence of TYRO3 in both PDL2
+ and PDL2 -DCs leads to enhanced production of type 2 chemokines and costimulatory molecules, resulting in exacerbated type 2 immune response.
We have recently described that T cells, once activated, produce the TAM receptor agonist PROS1 (5, 20) . PROS1 is also an agonist for TYRO3 (5, 20) . However, the expression profile of PROS1 with either isotype antibody or antibody against TYRO3 (a-TYRO3) for 10 days. Data are representative of two or three independent experiments. In all panels, each data point is from a different mouse or human, means ± SEM. Data were analyzed using unpaired Student's t test [(A) to (D)] or paired Student's t test (E).*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s., nonsignificant. S9, A and B) . These results indicated that T cells differentiating toward the T H 2 lineage sustain PROS1 expression, whereas expression is lost during T H 1 or T H 17 commitment. Gas6, the only other known agonist for TYRO3 (20, 21) , is not expressed in murine T cells (5) . Activation of T cell-receptor (TCR) signaling leads to the expression of PROS1 (5) . This depends on intrinsic IL-4 production as IL-4
-/--naïve CD4 + T cells failed to up-regulate Pros1 after TCR stimulation, but exogenous addition of IL-4 rescued this defect ( fig. S9C ). Pros1 up-regulation was also STAT6-dependent ( fig. S9C ). This is consistent with a previous report on the induction of Pros1 by IL-4 in T cells (22 fig. S9E ). Cd4-Cre + Pros1 flox/flox mice had fewer RBCs, increased BAL eosinophils, greater type 2 cytokine production from mLNs, and lower worm burden (Fig. 4, A to D) . Furthermore, OVA-papain immunization resulted in increased leukocytes and type 2 cytokine production by antigen-specific T cells in Cd4-Cre To explore whether this PROS1-TYRO3 axis functions in the regulation of type 2 immune responses in humans, we performed mixed-lymphocyte reactions (MLR) in the presence of an TYRO3-specific antibody or isotype control. We previously showed that human T cells express PROS1 upon activation (5) . The neutralization of TYRO3 led to a significant increase in the production of IL-13 but not IFN-g by the T cells, which underscores a selective inhibitory role of TYRO3 in type 2, but not type 1, immunity (Fig. 4E ). These results demonstrate that the TYRO3-PROS1 axis is an evolutionarily conserved negative regulator of the magnitude of the type 2 immune response.
A physiological immune response that limits the pathogen or pathogen-induced damage but avoids immunopathology has to be scalable. Such a response should have built-in sensors to monitor activation level and rheostats that vary the magnitude of the response. Here, we report the identification of a molecular mechanism that controls the intensity of type 2 immunity. In this mechanism, a RTK in DCs and its ligand produced by T H 2 cells function in concert to regulate the ensuing response. The same cytokine required for T H 2 commitment after T cell priming-IL-4 (23)-induces the sustained expression of Pros1 in T cells. This leads to the activation of the RTK TYRO3, expressed on DCs, which provides an inducible feedback mechanism at the DC-T cell interface. The overall effect of PROS1-TYRO3 signaling is to limit the magnitude of the type 2 immune response.
The critical role of TYRO3 in negatively regulating T H 2 responses makes this RTK an attractive pharmacological target for small molecules or biologics that activate or inhibit its function. The innate immune sensing mechanisms for the vast array of allergen and helminth products remain largely unknown. Therefore, therapeutic interventions in allergic disorders are currently limited to targeting downstream effectors of the type 2 immune response, such as histamine and leukotrienes, or to making use of broad immunosuppressive drugs, i.e., corticosteroids (24) . Our discovery of a self-limiting process intrinsic to type 2 immunity provides a novel opportunity to either enhance or inhibit this response. For example, activating TYRO3 would specifically lower allergic responses by preventing adaptive immune responses that function upstream of the generation of IgE, as well as the subsequent degranulation of eosinophils and mast cells. It could be equally attractive to extend this paradigm to parasitic infections where blocking TYRO3 may heighten type 2 response and improve expulsion of the parasites.
